Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Huls G.
Hilberink JR, et al.
Blood Cancer J. 2023 Jun 19;13(1):93. doi: 10.1038/s41408-023-00850-6.
Blood Cancer J. 2023.
PMID: 37336890
Free PMC article.